{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:21:38Z","timestamp":1753878098722,"version":"3.41.2"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPGN rep."],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec><jats:title>Objectives:<\/jats:title><jats:p>Chronic hepatitis B virus (HBV) genotype C infection is unlikely to show a good response to interferon (IFN). However, it is unknown whether a high dose of pegylated IFN (PEG\u2010IFN) treatment would be effective for hepatitis B e antigen (HBeAg)\u2010positive children with chronic HBV genotype C infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>HBeAg\u2010positive children and adolescents with chronic HBV genotype C infection were eligible for this study. To increase the dose of PEG\u2010IFN, all patients received PEG\u2010IFN\u2010\u03b1\u20102a (180 \u03bcg) without dose adjustment on the basis of body surface area for 48 weeks and were followed up for 24 weeks after the completion of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Thirteen patients (median age, 9 years) were enrolled prospectively for this study. One patient dropped out, and the remaining 12 patients were evaluated. Of the 12 patients, 11 received PEG\u2010IFN of 180 \u03bcg\/1.73 m<jats:sup>2<\/jats:sup> or more (median, 287 \u03bcg\/1.73 m<jats:sup>2<\/jats:sup>). Eight (67%) experienced HBeAg seroconversion, and 1 (8%) achieved hepatitis B surface antigen (HBsAg) loss at the end of follow\u2010up. There was a significant difference in the decrease of hepatitis B surface antigen levels from the baseline to week 24 of treatment between the responders and the nonresponders. Serum cytokines and chemokines were measured in 10 patients. The levels of C\u2010X\u2010C motif chemokine ligand 9, 10, 11, and 13 in the responders tended to be higher than those in the nonresponders during the first 24 weeks of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>A high dose of PEG\u2010IFN treatment was effective and safe. A decrease in the hepatitis B surface antigen level from baseline to week 24 of treatment might be a predictor of HBeAg seroconversion.<\/jats:p><\/jats:sec>","DOI":"10.1097\/pg9.0000000000000005","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T16:00:09Z","timestamp":1601049609000},"source":"Crossref","is-referenced-by-count":4,"title":["High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C"],"prefix":"10.1002","volume":"1","author":[{"given":"Haruki","family":"Komatsu","sequence":"first","affiliation":[{"name":"Department of Pediatrics Sakura Medical Center Toho University Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayano","family":"Inui","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hepatology and Gastroenterology Eastern Yokohama Hospital Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiyo","family":"Yoshio","sequence":"additional","affiliation":[{"name":"Liver Diseases, Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kanto","sequence":"additional","affiliation":[{"name":"Liver Diseases, Research Center for Hepatitis and Immunology National Center for Global Health and Medicine Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichiro","family":"Umetsu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hepatology and Gastroenterology Eastern Yokohama Hospital Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Tsunoda","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hepatology and Gastroenterology Eastern Yokohama Hospital Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoo","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hepatology and Gastroenterology Eastern Yokohama Hospital Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.05.016"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_8_4_1","first-page":"370","article-title":"Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"672","author":"EASL 2017","year":"2017","journal-title":"J Hepatol"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30050"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","unstructured":"YuenMF ChenDS DusheikoGM et al. Hepatitis B virus infection.Nat Rev Dis Primers.2018;418035","DOI":"10.1038\/nrdp.2018.35"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043470"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17701-0"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2012.01087.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28282"},{"key":"e_1_2_8_12_1","first-page":"115","article-title":"Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C","volume":"201","author":"The French METAVIR Cooperative Study Group","year":"1994","journal-title":"Hepatology"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2006.07.014"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165674"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13154"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-019-00303-w"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13165"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.08.061"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12400"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22956"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2008.11.007"},{"key":"e_1_2_8_22_1","unstructured":"ClementeMG AntonucciR SotgiuG et al. Present and future management of viral hepatitis B and C in children.Clin Res Hepatol Gastroenterol.2020"}],"container-title":["JPGN Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/PG9.0000000000000005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T14:05:44Z","timestamp":1749737144000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/PG9.0000000000000005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1097\/PG9.0000000000000005"],"URL":"https:\/\/doi.org\/10.1097\/pg9.0000000000000005","archive":["Portico"],"relation":{},"ISSN":["2691-171X","2691-171X"],"issn-type":[{"type":"print","value":"2691-171X"},{"type":"electronic","value":"2691-171X"}],"subject":[],"published":{"date-parts":[[2020,8,19]]},"article-number":"e005"}}